iPSC Differentiation into CD34+ and NK Cells via Normoxia-Hypoxia Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing iPSC differentiation into CD34+ cells and NK cells are inefficient, requiring long times and resulting in low yields, which hinders their clinical application.
Innovation Solution
A normoxia+hypoxia induction culture method using a specific sequence of culture media stages, including E8 complete medium, SPM1, SPM2, and SPM3, to promote rapid and high-yield differentiation of iPSCs into CD34+ cells and subsequently into NK cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation methods are used to induce iPSC differentiation into CD34+ cells and NK cells, then the differentiation process can be completed, but the time required is long and the yield is low
Solution Approach 1:
The differentiation process is divided into four distinct stages with specific culture media and conditions: Stage 1 (days 0-3) uses E8 complete medium for embryoid body formation, Stage 2 (days 4-7) uses SPM1 medium for mesodermal differentiation, Stage 3 (days 8-14) uses SPM2 medium for hematopoietic differentiation, and Stage 4 (days 15-21) uses SPM3 medium for NK cell differentiation. This segmentation allows optimized conditions for each stage, significantly improving both speed and yield.
Solution Approach 2:
The patent employs dynamic changes in culture media composition and oxygen tension parameters throughout the differentiation process. Oxygen tension is adjusted from normoxia in early stages to hypoxia in later stages, while culture media are sequentially changed from E8 complete medium to SPM1, SPM2, and SPM3 media with progressively specialized compositions. These parameter changes drive the differentiation process forward efficiently, reducing time and increasing yield.
2Reliability
If conventional differentiation methods are used, then iPSCs can be differentiated into NK cells, but the cytotoxic function against tumor cells is insufficient
Solution Approach 1:
The patent introduces specific intermediary substances and growth factors at each differentiation stage that mediate the transition and enhance cell function. Stage 1 uses ROCK pathway inhibitors and polyvinyl alcohol to form proper embryoid bodies, Stage 2 uses GSK-3B inhibitors to promote mesodermal differentiation, Stage 3 uses TGF-β inhibitors to enhance hematopoietic commitment, and Stage 4 uses NK cell-specific growth factors to develop cytotoxic function. These intermediaries ensure high-quality NK cells with strong tumor-killing capability.
Solution Approach 2:
The culture media are formulated as composite systems combining multiple growth factors, cytokines, and signaling molecules in specific concentrations and combinations. Each media formulation (E8 complete medium, SPM1, SPM2, SPM3) is a composite designed to support specific differentiation objectives, with combinations of growth factors that synergistically enhance both NK cell yield and cytotoxic function simultaneously.
Data Source
AI summary
The present invention discloses a method and its application for inducing iPSC differentiation to obtain CD34+cells and NK cells. The method utilizes the three-dimensional structure of the embryoid bodies to provide a favorable differentiation microenvironment for iPSC differentiation, and can start producing a high proportion of CD34+cells on the 4th day under hypoxic induction culture conditions. Subsequently, the production of iPSC induced NK cell differentiation is significantly increased by adhering to the embryoid bodies wall or digesting and resuspension induction, And the induced differentiation of NK cells can exert a killing effect on tumor cells in a short period of time, with strong tumor killing ability, suitable for the production and clinical application of large-scale cell preparations.